References
- Anzenbacher P, Anzenbacherova E. (2001). Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737–47
- Bajpai P, Sangar MC, Singh S, et al. (2013). Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. J Biol Chem 288:4436–51
- de Graaf C, Oostenbrink C, Keizers PH, et al. (2007). Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr Drug Metab 8:59–77
- Dorado P, Penas-Lledo EM, Llerena A. (2007). CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8:1597–608
- Hayhurst GP, Harlow J, Chowdry J, et al. (2001). Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem J 355:373–9
- Hibino H, Tani K, Ikebuchi K, et al. (1999). The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Blood 93:2839–48
- Hichiya H, Kuramoto S, Yamamoto S, et al. (2004). Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19. Biochem Pharmacol 68:165–75
- Igarashi T, Sakuma T, Isogai M, et al. (1997). Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Arch Biochem Biophys 339:85–91
- Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
- Iwata H, Fujita K, Kushida H, et al. (1998). High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315–25
- Kishi N, Sato K, Sasaki E, Okano H. (2014). Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ 56:53–62
- Kiyotani K, Shimizu M, Kumai T, et al. (2010). Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur J Clin Pharmacol 66:1065–8
- Lake BG, Walters DG, Gangolli SD. (1989). Comparison of the metabolism and disposition of [3–14C]coumarin in the rat and marmoset (Callithrix jacchus). Toxicol Lett 45:299–306
- Madani S, Paine MF, Lewis L, et al. (1999). Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharmaceut Res 16:1199–205
- Narimatsu S, Nakata T, Shimizudani T, et al. (2011). Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19. Chem Biol Interact 189:146–52
- Niwa T, Okada K, Hiroi T, et al. (2008). Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 31:348–51
- Okano H, Hikishima K, Iriki A, Sasaki E. (2012). The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin Fetal Neonatal Med 17:336–40
- Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8
- Paine MJ, McLaughlin LA, Flanagan JU, et al. (2003). Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021–7
- Phillips AH, Langdon RG. (1962). Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 237:2652–60
- Prueksaritanont T, Dwyer LM, Cribb AE. (1995). (+)-Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 50:1521–5
- Ramamoorthy A, Flockhart DA, Hosono N, et al. (2010). Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet Genomics 20:451–4
- Rowland P, Blaney FE, Smyth MG, et al. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–22
- Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
- Shimizudani T, Nagaoka K, Hanioka N, et al. (2010). Comparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys. Chem Biol Interact 183:67–78
- Uehara S, Murayama N, Nakanishi Y, et al. (2014). Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica 44:769–74
- Uehara S, Murayama N, Nakanishi Y, et al. (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654–61
- Uehara S, Murayama N, Yamazaki H, Uno Y. (2010). A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica 40:621–9
- Uno Y, Uehara S, Kohara S, et al. (2014). Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. Drug Metab Dispos 42:1407–10
- Wiltshire HR, Sutton BM, Heeps G, et al. (1997). Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 27:557–71
- Yamazaki H, Nakamura M, Komatsu T, et al. (2002). Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329–37